Journal Information
Vol. 46. Issue S2.
1º Congresso CancerThera
Pages S24-S25 (April 2024)
Vol. 46. Issue S2.
1º Congresso CancerThera
Pages S24-S25 (April 2024)
Full text access
18F-FLUORIDE PET/CT vs 18F-PSMA-1007 TO DETECT BONE METASTASES IN PROSTATE CANCER – A HEAD-TO-HEAD PROSPECTIVE COMPARISON
Visits
847
Beatriz Birelli do Nascimentoa, Allan Santosb, Natalia Tobarc, Fabiana Moria, Mariana Camachod, Mariana Limab, Edna Brunettoc, Sergio Brunettoc, Anelise Ruzzarinc, Juliana Ciampie, Marina Silveiraf, Gardenia Oliveira Barbosac, Wagner Matheusg, Ubirajara Ferreirag, Elba Etchebehereb
a Instituto de Diagnósticos (IDS), Sorocaba, SP, Brazil
b Universidade Estadual de Campinas (UNICAMP) - Medicina Nuclear e MND, Campinas, SP, Brazil
c Universidade Estadual de Campinas (UNICAMP) - Medicina Nuclear, Campinas, SP, Brazil
d MND - Medicina Nuclear de Campinas, Campinas, SP, Brazil
e Cyclobras, Campinas, SP, Brazil
f CDTN / CNEN, Belo Horizonte, MG, Brazil
g Universidade Estadual de Campinas (UNICAMP) – Urologia, Campinas, SP, Brazil
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 46. Issue S2

1º Congresso CancerThera

More info
Introduction/Justification

There have been no head-to-head prospective studies comparing the ability of 18F-Fluoride PET/CT and 18F-PSMA-1007 PET/CT to detect bone metastases due to prostate cancer. So, this study aims to investigate the capacity of 18F-PSMA-1007 to detect bone metastases compared to the reference standard (18F-Fluoride PET/CT) in PCa patients, considering mainly the presence or absence, number and biodistribution of lesions.

Objectives

This prospective study aimed to compare the ability of 18F-PSMA-1007 PET/CT and 18F-Fluoride PET/CT to detect bone metastases.

Materials and Methods

Twenty-eight patients with prostate cancer biochemical recurrence were submitted to both 18F-PSMA-1007 PET/CT and 18F-fluoride PET/CT studies. These two radiotracers evaluated the presence or absence, number of lesions, body and bone localization, lesion pattern, and probability of malignancy.

Results

Twenty-eight patients with prostate cancer biochemical recurrence, mean age of 70.8 ± 8.7 years; Gleason score = 7.72 ± 1.23 and the mean total PSA = 50.2 ± 183.9 ng/mL were included. On a per-patient basis, considering that 18F-Fluoride PET/CT is the gold standard, the 18F-PSMA-1007 PET/CT presented a concordance rate of 96.43%, sensitivity (S) of 92.3%, specificity (E) of 100%, predictive positive value (PPV) of 100% and predictive negative value (PNV) of 93.80% on lesion detection. Evaluating the number of lesions, 18F-PSMA-1007 PET/CT determined a PPV of 91.8% and sensitivity of 86.5%. Bone localization in 18F- Fluoride and 18F-PSMA-1007 were predominant in the dorsal spine (34.62%/62.65%), ribs (32.69%/32.65%)and pelvis (9.62%/12.24%), respectively. Both studies had a concordant rate of 80.76% on rib evaluation, the most conflicting site of uptake between the methods in actual literature.

Conclusion

18F-PSMA-1007 has the same ability as 18F-Fluoride to detect PCa bone metastasis in biochemical recurrence, with concordance of 96,43% and 80,00% on a per-patient and per-lesion evaluation, respectively. Both studies demonstrated predominancy of sclerotic and medullar lesions, located preferentially on dorsal spine and ribs, being the last one concordant in 80,76% of studies.

Keywords:
Bone metastasis
Fluoride PET/CT
Prostate cancer
PSMA PET/CT
18F-PSMA-1007
Full text is only available in PDF
Download PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Article options
Tools